Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics

Wait 5 sec.

Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe Telix's fibroblast activation protein (FAP) targeting therapy candidate (TLX400-Tx) has been selected for evaluation with terbium-161 based on clinical potential and...